Prothena Corporation PLC
prothena.comProthena Corporation PLC (NASDAQ: PRTA) is a clinical-stage biopharmaceutical company that discovers and develops protein dysregulation therapies, primarily targeting neurodegenerative diseases and other conditions driven by misfolded proteins. The company generates revenue through collaboration and licensing agreements rather than product sales, as its drug candidates remain in clinical development as of the 10-K filed 2026-02-27. Prothena is incorporated in Ireland and operates as a development-stage business, meaning it carries no commercial product revenue and funds operations through partnership payments and capital markets. The company's pipeline consists of biologic candidates filed under Biologics License Applications, which, if approved, would qualify for 12-year reference product exclusivity under the Biologics Price Competition and Innovation Act. With no approved products disclosed in the filing excerpts, the business is pre-revenue from product sales and dependent on collaboration income and cash reserves to fund ongoing trials.
Products & Services
Clinical-stage biologic drug candidates targeting protein dysregulation and neurodegenerative diseases. Candidates are filed as biologics under BLA pathway and would carry 12-year reference product exclusivity if approved.
Revenue Model
Collaboration and licensing agreements. No commercial product revenue disclosed in the FY2025 10-K (filed 2026-02-27). Revenue is milestone- and royalty-based from partnership arrangements.
Customers & Markets
Pharmaceutical and biotechnology collaboration partners. End markets are neurodegenerative and protein misfolding diseases. No commercial customers disclosed in the filing excerpts.
Geographic Exposure
Incorporated in Ireland. U.S. FDA regulatory framework governs drug approval pathway. No specific revenue by geography disclosed in the filing excerpts.
Financial Snapshot
Loading...
